Brendel Financial Advisors LLC Invests $2.85 Million in Pfizer Inc. (NYSE:PFE)

Brendel Financial Advisors LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 99,131 shares of the biopharmaceutical company’s stock, valued at approximately $2,854,000. Pfizer accounts for approximately 1.9% of Brendel Financial Advisors LLC’s investment portfolio, making the stock its 23rd biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Commerzbank Aktiengesellschaft FI grew its stake in Pfizer by 5.0% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 241,832 shares of the biopharmaceutical company’s stock valued at $6,962,000 after acquiring an additional 11,497 shares during the period. PSI Advisors LLC grew its stake in Pfizer by 19.1% in the 4th quarter. PSI Advisors LLC now owns 29,508 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 4,729 shares during the period. Cetera Trust Company N.A acquired a new stake in Pfizer in the 4th quarter valued at $53,000. Hussman Strategic Advisors Inc. grew its stake in Pfizer by 21.2% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 126,000 shares of the biopharmaceutical company’s stock valued at $3,628,000 after acquiring an additional 22,000 shares during the period. Finally, CWM LLC grew its stake in Pfizer by 1.0% in the 4th quarter. CWM LLC now owns 1,126,839 shares of the biopharmaceutical company’s stock valued at $32,442,000 after acquiring an additional 11,167 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Up 2.4 %

Shares of NYSE PFE traded up $0.61 during trading on Friday, hitting $26.00. 38,372,801 shares of the company were exchanged, compared to its average volume of 34,236,664. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a fifty day moving average price of $27.11 and a 200-day moving average price of $28.65. The firm has a market capitalization of $147.23 billion, a PE ratio of 72.22, a P/E/G ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.14 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.